C4.4A/LYPD3 Antibody (lupartumab) [DyLight 680]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28646FR
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
DyLight 680 (Excitation = 692 nm, Emission = 712 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # lupartumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
LYPD3 / C4.4A
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for C4.4A/LYPD3 Antibody (lupartumab) [DyLight 680]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: C4.4A/LYPD3
Long Name
Leucine Rich Repeat and Fibronectin Type III Domain Containing 3
Alternate Names
LYPD3, MIG-C4
Gene Symbol
LYPD3
Additional C4.4A/LYPD3 Products
Product Documents for C4.4A/LYPD3 Antibody (lupartumab) [DyLight 680]
Product Specific Notices for C4.4A/LYPD3 Antibody (lupartumab) [DyLight 680]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...